Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Copy number variable microRNAs and single nucleotide variants as genetic risk factors for schizophrenia

EF 2013-14

Résumé
Schizophrenia is a serious mental illness that affects up to 1% of the world’s population. The symptoms vary, but often include auditory hallucinations, delusions, disorganized thinking, and social dysfunction. Genetics are understood to play an important role in causing schizophrenia. For example, in a pair of identical twins, if one twin has schizophrenia, the other has an estimated 50% chance of being diagnosed with the disease at some point. In fraternal (sibling) twins where one twin has schizophrenia, this likelihood is only about 15%. The precise role of genetics in the causation of schizophrenia is not known at this time. However, we are beginning to know something about rare molecular genetic changes that may contribute to the risk of developing the disease. The best evidence so far, for changes that can disrupt genes, involves structural variants called copy number variants (CNVs). CNVs are like whole paragraphs of the genetic code (DNA) that are duplicated (extra) or deleted (missing). The CNV that has been most often linked to schizophrenia involves the deletion of a region on chromosome 22. About one in every four patients with “22q11.2 deletion syndrome” develops schizophrenia, about a 20- to 25-fold greater risk than the general population. Another way that genes can be disrupted is through microRNAs. These are small molecules encoded for in our DNA that act to modify the expression of genes that code for proteins. Abnormal levels of microRNAs have previously been linked to schizophrenia. Interestingly, an important gene involved in the creation of microRNAs is disrupted in 22q11.2 deletion syndrome. My research over the summer has found that patients with schizophrenia are significantly enriched for CNVs that disrupt the DNA sequence encoding microRNAs, when compared with a control population. My proposed research will examine for comparable enrichment in cohorts of patients with 22q11.2 deletion syndrome compared to a control population. In addition to the schizophrenia case-control study, we have data collected on families where two or more individuals are affected with schizophrenia. I will perform a similar analysis with these data, comparing affected to unaffected family members, as well as to controls. Furthermore, I will compare changes in smaller sections of DNA encoding for microRNAs that are overlooked when analyzing CNVs. The objective of my research is to investigate the potential significance of microRNA content in rare CNVs in schizophrenia and 22q11.2 deletion syndrome. Studies of this nature have never been conducted before for these diseases. The results of this research will provide evidence for or against enrichment or disruption of microRNA content in CNVs in schizophrenia and 22q11.2 deletion syndrome. I will examine the genes that the disease-associated microRNAs are predicted to target, to see what functions these genes serve within the human body. For example, my research has demonstrated that, in schizophrenia, there is enrichment for microRNAs whose target genes are involved in brain-specific pathways. This research has implications for the future clinical interpretation of CNVs. There is potential that it will become clinically important to consider the microRNA content of CNVs when examining patients’ genetic test results. The results could also provide a basis for microRNA-based therapeutics in schizophrenia. Drugs that could augment or reduce levels of certain microRNAs in the body could have the potential to diminish or halt the development of schizophrenia.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311765
Name
Warnica William
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Copy number variable microRNAs and single nucleotide variants as genetic risk factors for schizophrenia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Biostatistics; Copy Number Variation; Genetics; Microrna; Schizophrenia; Single Nucleotide Variant; Variable Expression
Abstract
Schizophrenia is a serious mental illness that affects up to 1% of the world’s population. The symptoms vary, but often include auditory hallucinations, delusions, disorganized thinking, and social dysfunction. Genetics are understood to play an important role in causing schizophrenia. For example, in a pair of identical twins, if one twin has schizophrenia, the other has an estimated 50% chance of being diagnosed with the disease at some point. In fraternal (sibling) twins where one twin has schizophrenia, this likelihood is only about 15%. The precise role of genetics in the causation of schizophrenia is not known at this time. However, we are beginning to know something about rare molecular genetic changes that may contribute to the risk of developing the disease. The best evidence so far, for changes that can disrupt genes, involves structural variants called copy number variants (CNVs). CNVs are like whole paragraphs of the genetic code (DNA) that are duplicated (extra) or deleted (missing). The CNV that has been most often linked to schizophrenia involves the deletion of a region on chromosome 22. About one in every four patients with “22q11.2 deletion syndrome” develops schizophrenia, about a 20- to 25-fold greater risk than the general population. Another way that genes can be disrupted is through microRNAs. These are small molecules encoded for in our DNA that act to modify the expression of genes that code for proteins. Abnormal levels of microRNAs have previously been linked to schizophrenia. Interestingly, an important gene involved in the creation of microRNAs is disrupted in 22q11.2 deletion syndrome. My research over the summer has found that patients with schizophrenia are significantly enriched for CNVs that disrupt the DNA sequence encoding microRNAs, when compared with a control population. My proposed research will examine for comparable enrichment in cohorts of patients with 22q11.2 deletion syndrome compared to a control population. In addition to the schizophrenia case-control study, we have data collected on families where two or more individuals are affected with schizophrenia. I will perform a similar analysis with these data, comparing affected to unaffected family members, as well as to controls. Furthermore, I will compare changes in smaller sections of DNA encoding for microRNAs that are overlooked when analyzing CNVs. The objective of my research is to investigate the potential significance of microRNA content in rare CNVs in schizophrenia and 22q11.2 deletion syndrome. Studies of this nature have never been conducted before for these diseases. The results of this research will provide evidence for or against enrichment or disruption of microRNA content in CNVs in schizophrenia and 22q11.2 deletion syndrome. I will examine the genes that the disease-associated microRNAs are predicted to target, to see what functions these genes serve within the human body. For example, my research has demonstrated that, in schizophrenia, there is enrichment for microRNAs whose target genes are involved in brain-specific pathways. This research has implications for the future clinical interpretation of CNVs. There is potential that it will become clinically important to consider the microRNA content of CNVs when examining patients’ genetic test results. The results could also provide a basis for microRNA-based therapeutics in schizophrenia. Drugs that could augment or reduce levels of certain microRNAs in the body could have the potential to diminish or halt the development of schizophrenia.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Warnica, William
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~